Business Context and Reporting Period
Company: TECHNE Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2002
Overview: TECHNE is a holding company with two primary operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, MN, and R&D Systems Europe Ltd. in Abingdon, England. The company operates in two main segments: Hematology (controls and calibrators for blood analysis) and Biotechnology (cytokines, antibodies, and assay kits for research and clinical diagnostics). The company also holds equity interests in ChemoCentryx, Inc. (26%) and Discovery Genomics, Inc. (39%).
Key Financial Metrics
| Metric | Fiscal 2002 | Fiscal 2001 | Fiscal 2000 |
|---|---|---|---|
| Net Sales | $130,900,395 | $115,356,562 | $103,838,155 |
| Gross Margin | 75.2% | 75.4% | 74.2% |
| Net Earnings | $27,129,669 | $34,045,376 | $26,582,797 |
| Diluted EPS | $0.64 | $0.80 | $0.63 |
| Operating Cash Flow | $27,667,227 | $46,371,711 | $38,739,403 |
| Capital Expenditures | $22,276,262 | $6,814,953 | $30,367,862 |
| Long-Term Debt | $17,100,652 | $18,050,289 | $18,935,049 |
| Cash & Equivalents | $26,392,480 | $21,267,791 | $17,356,108 |
| Total Assets | $238,246,959 | $215,525,113 | $180,410,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% to $130.9 million, driven primarily by a 15% increase in Biotechnology Division sales and a 14% increase in R&D Europe sales.
- Profitability Decline: Net earnings decreased 20% to $27.1 million. This decline was primarily due to a one-time $17.5 million litigation settlement with Amgen Inc. recorded in the fourth quarter. Excluding this charge, earnings before taxes would have increased to approximately $55.2 million.
- Margin Pressure: Gross margin decreased slightly to 75.2% from 75.4%. The Hematology Division margin dropped to 45.0% due to higher raw material (blood) costs in the second quarter, while the Biotechnology Division margin improved to 79.2% due to manufacturing efficiencies.
- Capital Spending: Capital expenditures surged to $22.3 million (from $6.8 million in 2001) due to the purchase of adjacent property ($8.9 million) and construction of a parking ramp and facility infill ($7.8 million).
- Investment Losses: Research and development expenses included operating losses from equity method investments in ChemoCentryx ($1.35 million) and Discovery Genomics ($0.5 million).
Guidance, Outlook, and Risks
Management Commentary: Management expects to meet future cash requirements through current funds and operating cash flow. The company plans to retain earnings for business reinvestment and does not anticipate paying dividends. Construction on the new facility expansion is expected to be completed in late fiscal 2003.
Key Risks and Contingencies:
- Legal Settlement: The $17.5 million Amgen settlement was paid in full in June 2002. Management states future operations will not be adversely affected.
- Investment Portfolio Risk: Approximately $3.5 million of short-term investments were held in a brokerage account that entered bankruptcy in September 2001. Management expects full recovery but notes the resolution is pending.
- Regulatory & Patent Risks: The company faces risks regarding FDA approvals for clinical diagnostic kits and potential patent infringement claims, as it has not conducted a comprehensive infringement study for all products.
- Raw Material Costs: Volatility in the supply and cost of human blood (due to HIV/hepatitis testing requirements) impacts the Hematology Division's margins.
- Accounting Changes: The company adopted SFAS No. 142 (Goodwill) on July 1, 2002, which stops the amortization of goodwill but requires periodic impairment testing.
Investor Verification Checklist
- Amgen Settlement Impact: Verify the full $17.5 million charge was a one-time event and confirm no further liabilities exist regarding the Amgen dispute.
- Investment Recovery: Monitor the status of the $3.5 million held in the bankrupt brokerage account to ensure full recovery of assets.
- Capital Expenditure ROI: Assess the timeline and cost overruns for the $16 million remaining construction costs on the new facility expansion.
- Raw Material Pricing: Track the stability of blood supply costs to evaluate the sustainability of Hematology Division margins.
- Equity Method Investments: Review the financial performance of ChemoCentryx and Discovery Genomics, as their losses directly impact TECHNE's R&D expenses and net income.